Many emerging new drugs have recently been trialled for treatment of early and advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role, mostly in patients with relapsed and metastatic disease after failure of chemotherapy with antracyclines.METHODS: A phase II study was started in order to evaluate the activity and toxicity of a combination of paclitaxel and gemcitabine in a biweekly schedule on metastatic breast cancer patients previously treated with antracyclines.RESULTS: Twenty-five patients received paclitaxel (150 mg/mq) by 3-hours infusion, followed by gemcitabine (2000 mg/mq) given as a 60 min i.v. infusion (day 1-14) for a maximum of eight cycles. In all patients treatment was evaluated for toxicity and efficacy; four patients (16%) achieved a complete response, 12 (48%) a partial response giving an overall objective response rate of 64%. Stable disease was documented in 5 patients (20%) and progressive disease occurred in 4 patients (16%). CONCLUSION: The schedule of treatment was safe and tolerable from a haematological and non-haematological point of view. These data confirm that the combination of gemcitabine and paclitaxel on a biweekly basis is an effective and well-tolerated regimen in breast cancer patients with prior therapeutic exposure to antracyclines.

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer / Tomao, Silverio; Adriana, Romiti; Tomao, Federica; Marisa Di, Seri; Giuliana, Caprio; Spinelli, GIAN PAOLO; Edmondo, Terzoli; Luigi, Frati. - In: BMC CANCER. - ISSN 1471-2407. - ELETTRONICO. - 24:6(2006), p. 137. [10.1186/1471-2407-6-137]

A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer

TOMAO, SILVERIO;TOMAO, FEDERICA;SPINELLI, GIAN PAOLO;
2006

Abstract

Many emerging new drugs have recently been trialled for treatment of early and advanced breast cancer. Among these new agents paclitaxel and gemcitabine play a crucial role, mostly in patients with relapsed and metastatic disease after failure of chemotherapy with antracyclines.METHODS: A phase II study was started in order to evaluate the activity and toxicity of a combination of paclitaxel and gemcitabine in a biweekly schedule on metastatic breast cancer patients previously treated with antracyclines.RESULTS: Twenty-five patients received paclitaxel (150 mg/mq) by 3-hours infusion, followed by gemcitabine (2000 mg/mq) given as a 60 min i.v. infusion (day 1-14) for a maximum of eight cycles. In all patients treatment was evaluated for toxicity and efficacy; four patients (16%) achieved a complete response, 12 (48%) a partial response giving an overall objective response rate of 64%. Stable disease was documented in 5 patients (20%) and progressive disease occurred in 4 patients (16%). CONCLUSION: The schedule of treatment was safe and tolerable from a haematological and non-haematological point of view. These data confirm that the combination of gemcitabine and paclitaxel on a biweekly basis is an effective and well-tolerated regimen in breast cancer patients with prior therapeutic exposure to antracyclines.
gemcitabine; paclitaxel; breast cancer
01 Pubblicazione su rivista::01a Articolo in rivista
A phase II trial of a biweekly combination of paclitaxel and gemcitabine in metastatic breast cancer / Tomao, Silverio; Adriana, Romiti; Tomao, Federica; Marisa Di, Seri; Giuliana, Caprio; Spinelli, GIAN PAOLO; Edmondo, Terzoli; Luigi, Frati. - In: BMC CANCER. - ISSN 1471-2407. - ELETTRONICO. - 24:6(2006), p. 137. [10.1186/1471-2407-6-137]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/496500
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 15
social impact